- Home
- TDC vs KNSA Comparison
TDC vs KNSA Comparison
Compare TDC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDC
- KNSA
- Stock Information
- Founded
- TDC 1979
- KNSA 2015
- Country
- TDC United States
- KNSA United Kingdom
- Employees
- TDC N/A
- KNSA N/A
- Industry
- TDC Computer Software: Prepackaged Software
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TDC Technology
- KNSA Health Care
- Exchange
- TDC Nasdaq
- KNSA Nasdaq
- Market Cap
- TDC 2.2B
- KNSA 1.9B
- IPO Year
- TDC 2007
- KNSA 2018
- Fundamental
- Price
- TDC $21.69
- KNSA $28.23
- Analyst Decision
- TDC Hold
- KNSA Strong Buy
- Analyst Count
- TDC 9
- KNSA 5
- Target Price
- TDC $29.75
- KNSA $38.80
- AVG Volume (30 Days)
- TDC 972.7K
- KNSA 713.9K
- Earning Date
- TDC 08-04-2025
- KNSA 07-22-2025
- Dividend Yield
- TDC N/A
- KNSA N/A
- EPS Growth
- TDC 241.18
- KNSA N/A
- EPS
- TDC 1.41
- KNSA N/A
- Revenue
- TDC $1,703,000,000.00
- KNSA $481,166,000.00
- Revenue This Year
- TDC N/A
- KNSA $37.21
- Revenue Next Year
- TDC $0.67
- KNSA $5.32
- P/E Ratio
- TDC $15.57
- KNSA N/A
- Revenue Growth
- TDC N/A
- KNSA 59.45
- 52 Week Low
- TDC $18.43
- KNSA $17.38
- 52 Week High
- TDC $35.60
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- TDC 47.86
- KNSA 51.94
- Support Level
- TDC $21.35
- KNSA $27.62
- Resistance Level
- TDC $22.49
- KNSA $28.69
- Average True Range (ATR)
- TDC 0.47
- KNSA 1.11
- MACD
- TDC -0.04
- KNSA -0.31
- Stochastic Oscillator
- TDC 40.65
- KNSA 32.65
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.